BLOG

Phase 2 Trial Evaluating LUM-201 for Treatment of Growth Hormone Deficiency

Pisit “Duke” Pitukcheewanont, MD, Chief Medical Officer for Lumos Pharma, discusses a phase 2 trial evaluating LUM-201 (ibutamoren) for treatment of growth hormone deficiency.